• Agios Pharmaceuticals (AGIO) NDA Submission of Enasidenib (AG-221) for Acute Myeloid Leukemia

       (0 reviews)

    Biotech_Forecast
    Clinical and Regulatory
    Event Type: NDA Submission
    Timing: Q4 2016
    Designation(s): Fast Track, Orphan Drug

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Oncology
    Indication: Acute Myeloid Leukemia
    Lead Indication?: No
    Treatment Name: Enasidenib (AG-221)

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Agios Pharmaceuticals
    Stock Symbol: AGIO
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExMTI4MDMyJkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
    Partnership: Yes

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement

    Quote

    Agios Pharmaceuticals, Inc. (the “Company”) today announced that its collaboration partner Celgene Corporation (“Celgene”) expects to submit a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for enasidenib (AG-221), a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-2 (“IDH2”), in relapsed and/or refractory acute myeloid leukemia (“AML”). The NDA will be based on data from the ongoing phase 1/2 study of AG-221 in patients with advanced hematologic malignancies with an IDH2 mutation. The NDA submission is expected to occur by year-end 2016. Celgene will be discussing the planned enasidenib NDA submission at the Citi 11th Annual Biotech Conference in Boston in a webcast event on Wednesday, September 7, 2016 at 12:00 pm ET

     


      Report Event


    User Feedback

    There are no reviews to display.